HIV Medicine

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro
pp. 75-79(5)
Authors: Jevtović, DO; Salemović, D; Ranin, J; Pešić, I; Žerjav, S; Djurković-Djaković, O

Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme
pp. 80-85(6)
Authors: Wood, E; Hogg, RS; Yip, B; Moore, D; Harrigan, PR; Montaner, JSG

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda
pp. 86-91(6)
Authors: Penzak, SR; Kabuye, G; Mugyenyi, P; Mbamanya, F; Natarajan, V; Alfaro, RM; Kityo, C; Formentini, E; Masur, H

Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal
pp. 92-95(4)
Authors: Poupard, M; Ngom Gueye, NF; Thiam, D; Ndiaye, B; Girard, PM; Delaporte, E; Sow, PS; Landman, R

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death
pp. 96-104(9)
Authors: Holkmann Olsen, C; Mocroft, A; Kirk, O; Vella, S; Blaxhult, A; Clumeck, N; Fisher, M; Katlama, C; Phillips, AN; Lundgren, JD

Limitation of exercise capacity in nucleoside-treated HIV-infected patients with hyperlactataemia
pp. 105-111(7)
Authors: Duong, M; Dumas, JP; Buisson, M; Martha, B; Piroth, L; Grappin, M; Waldner, A; Chavanet, P; Portier, H

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin-2
pp. 112-123(12)

HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV
pp. 124-130(7)
Authors: Guiguet, M; Furco, A; Tattevin, P; Costagliola, D; Molina, J-M

Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
pp. 131-134(4)
Authors: Mallolas, J; Sarasa, M; Nomdedeu, M; Soriano, A; López-Púa, Y; Blanco, JL; Martínez, E; Gatell, JM